what is gray tirzepatide TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Is Tirzepatide safe for you?

Aleksandr Shapsis, MD

In patients with type 2 diabetes and high cardiovascularrisk, clinical trials have shown that GLP-1 receptor agonistsreduce the incidence of major adverse cardiovascular events.The effect of tirzepatide a dual incretin agonist of theGLP-1 and GIP receptors on cardiovascular outcomes isuncertain. In theSURPASS-CVOTtrial, patients40 years of age or older with type 2 diabetes, a BMIof at least 25, and atherosclerotic cardiovascular disease wererandomly assigned to receive a weekly subcutaneous injectionof tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), a GLP-1receptor agonist that has been shown to reduce the incidenceof cardiovascular events

Mounjaro and Wegovy are primarily used for weight loss

Whether at home, at work, or on the go, they fit seamlessly into your everyday lifestyle

EU recommends updating Wegovy (semaglutide 2.4 mg) label to reflect reduced heart failure symptoms and improved physical function in obesity-related HFpEF, following positive STEP HFpEF trials